Yale Researchers Developed AI Heart Disease Tool

The FDA granted breakthrough status to an artificial intelligence platform designed to detect a rare heart condition.

Updated on Oct. 1, 2026 in Heart Disease

Yale Researchers Developed AI Heart Disease Tool

Live Poll

Do you trust artificial intelligence to assist doctors in diagnosing serious heart conditions?

Yale scientists have developed an artificial intelligence platform capable of identifying transthyretin amyloid cardiomyopathy by analyzing electrocardiogram images. The FDA has granted the tool breakthrough device designation as it remains under regulatory review.

Why it matters

Amyloid cardiomyopathy is frequently underdiagnosed because its symptoms mimic other cardiovascular conditions. Identifying the disease early is critical as untreated cases carry an average life expectancy of just five years.

Researchers tested the AI model across eight distinct patient cohorts in the United States and Europe. The platform is also currently being evaluated in the TRACE-AI Network Study across 13 different health centers.

The players

Yale School of Medicine

This academic institution served as the primary site for the development of the artificial intelligence diagnostic tool.

FDA

This federal agency regulates medical devices and granted the tool breakthrough status under its program for innovative technologies.

National Institutes of Health

This primary agency of the United States government is responsible for biomedical and public health research.

Doris Duke Charitable Foundation

This private foundation provides grants to support medical research, environmental conservation, and the performing arts.

The details

The AI model was trained on electrocardiogram data from thousands of de-identified patients to recognize specific patterns associated with protein accumulation on the heart muscle. The research, supported by the National Institutes of Health and the Doris Duke Charitable Foundation, was published in the journal JAMA.

The article detailing the new AI tool was published on October 1, 2026.

Health Landscape

The development of this tool aligns with the FDA Breakthrough Devices Program, which accelerates the review process for technologies that address significant clinical needs. This initiative marks a broader shift toward using machine learning to solve diagnostic challenges in cardiovascular medicine.

This diagnostic tool aims to reduce the time patients spend searching for a correct diagnosis for their heart symptoms. Once approved, the platform could allow cardiologists to identify the disease earlier and initiate life-extending treatments sooner.

The takeaway

Artificial intelligence is increasingly playing a vital role in catching hard-to-diagnose conditions by identifying patterns invisible to the human eye. Patients with persistent, unexplained heart symptoms should discuss the possibility of amyloid cardiomyopathy with their primary cardiologist.